Cross sectional evaluation of growth, metabolic, and psychosocial issues of children with congenital adrenal hyperplasia
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- Prevalence of growth abnormalities, metabolic syndrome, pubertal abnormalities
Study Overview
Brief Summary
Congenital adrenal hyperplasia (CAH) is a common disorder (incidence 1:10,000 births) which presents as virilization in girls to life threatening adrenal crisis to milder non-classical forms later in life. To dismay, affected girls with CAH often face social stigma and abandonment to be later adopted by Hijra community. Affected infants may remain unrecognized and may succumb to adrenal crisis in mild infection. Delayed identification may compromise on the height outcomes, metabolic well being and quality of life of patients with CAH. Currently there is lack of data on the follow up outcomes of CAH patients. Hence a screening and monitoring framework is desirable for CAH subjects. Currently there is limited literature available on profile of medical and psychosocial morbidities as retrospective studies have evaluated only on handful of CAH patients. Thus, the current study will highlight the medical and psychosocial issues in patients with CAH for improved case management and health outcomes.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 28.00 Day(s) to 18.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Diagnosed cases of congenital adrenal hyperplasia detected with clinical features of CAH with elevated serum 17-hydroxy progesterone levels.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Prevalence of growth abnormalities, metabolic syndrome, pubertal abnormalities
Time Frame: Single
Secondary Outcomes
- Association between growth with cumulative steroid doses(Association between growth and serum 17OHP levels)
